Ardelyx resubmits NDA for Xphozah to US FDA
A first-in-class, phosphate absorption inhibitor, Xphozah will be used to control serum phosphate in adults with chronic kidney disease (CKD) on dialysis and who had an insufficient response
Lynch Regenerative Medicine (LRM) has closed its Series A financing round for the development and commercialisation of advanced skin rejuvenation and regeneration solutions.
The multi-year strategic partnership will leverage latest molecular profiling approaches guiding patient selection and participation to accelerate precision medicine approaches across five of the therapeutic programmes of Flare.